QIAGEN Stock Forecast, Price & News

+0.19 (+0.35 %)
(As of 09/17/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.57 million shs
Average Volume787,911 shs
Market Capitalization$12.39 billion
P/E Ratio26.38
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive QGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for QIAGEN and its competitors with MarketBeat's FREE daily newsletter.



QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.38 out of 5 stars

Medical Sector

1084th out of 1,351 stocks

Biological Products, Except Diagnostic Industry

164th out of 193 stocks

Analyst Opinion: 1.3Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

QIAGEN (NYSE:QGEN) Frequently Asked Questions

Is QIAGEN a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for QIAGEN in the last twelve months. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QIAGEN stock.
View analyst ratings for QIAGEN
or view top-rated stocks.

What stocks does MarketBeat like better than QIAGEN?

Wall Street analysts have given QIAGEN a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but QIAGEN wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting QIAGEN?

QIAGEN saw a decline in short interest in August. As of August 13th, there was short interest totaling 3,990,000 shares, a decline of 16.7% from the July 29th total of 4,790,000 shares. Based on an average trading volume of 748,200 shares, the short-interest ratio is currently 5.3 days. Currently, 1.8% of the shares of the company are sold short.
View QIAGEN's Short Interest

When is QIAGEN's next earnings date?

QIAGEN is scheduled to release its next quarterly earnings announcement on Tuesday, October 26th 2021.
View our earnings forecast for QIAGEN

How were QIAGEN's earnings last quarter?

QIAGEN (NYSE:QGEN) released its earnings results on Thursday, July, 29th. The company reported $0.67 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.66 by $0.01. The business earned $567.31 million during the quarter, compared to analyst estimates of $562.35 million. QIAGEN had a trailing twelve-month return on equity of 21.31% and a net margin of 21.92%. During the same quarter last year, the firm posted $0.55 EPS.
View QIAGEN's earnings history

How has QIAGEN's stock price been impacted by COVID-19?

QIAGEN's stock was trading at $41.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, QGEN shares have increased by 32.2% and is now trading at $54.34.
View which stocks have been most impacted by COVID-19

What guidance has QIAGEN issued on next quarter's earnings?

QIAGEN updated its FY 2021 earnings guidance on Tuesday, August, 10th. The company provided earnings per share guidance of $2.420-$ for the period, compared to the Thomson Reuters consensus estimate of $2.470. The company issued revenue guidance of $2.09 B-, compared to the consensus revenue estimate of $2.27 billion.

What price target have analysts set for QGEN?

12 equities research analysts have issued 1 year price targets for QIAGEN's shares. Their forecasts range from $49.53 to $59.00. On average, they anticipate QIAGEN's share price to reach $53.61 in the next year. This suggests that the stock has a possible downside of 1.3%.
View analysts' price targets for QIAGEN
or view top-rated stocks among Wall Street analysts.

Who are QIAGEN's key executives?

QIAGEN's management team includes the following people:
  • Thierry Bernard, Chief Executive Officer & Managing Director
  • Barthold Piening, Senior Vice President & Head-Global Operations
  • Roland Sackers, Chief Financial Officer & Managing Director
  • Stephany Foster, Senior Vice President & Head-Human Resources
  • Thomas Schweins, Senior Vice President-Life Science Business Area

What is Thierry Bernard's approval rating as QIAGEN's CEO?

33 employees have rated QIAGEN CEO Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among QIAGEN's employees.

Who are some of QIAGEN's key competitors?

What other stocks do shareholders of QIAGEN own?

Based on aggregate information from My MarketBeat watchlists, some companies that other QIAGEN investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).

What is QIAGEN's stock symbol?

QIAGEN trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Who are QIAGEN's major shareholders?

QIAGEN's stock is owned by many different retail and institutional investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (8.67%), Vanguard Group Inc. (3.32%), BlackRock Inc. (2.12%), Millennium Management LLC (1.53%), State Street Corp (0.90%) and Legal & General Group Plc (0.85%).

Which institutional investors are selling QIAGEN stock?

QGEN stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Goldman Sachs Group Inc., Senator Investment Group LP, Millennium Management LLC, DekaBank Deutsche Girozentrale, Korea Investment CORP, AQR Capital Management LLC, and Los Angeles Capital Management LLC.

Which institutional investors are buying QIAGEN stock?

QGEN stock was purchased by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Premier Fund Managers Ltd, Jennison Associates LLC, Grandeur Peak Global Advisors LLC, Morgan Stanley, Morgan Stanley, Balyasny Asset Management LLC, and First Trust Advisors LP.

How do I buy shares of QIAGEN?

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is QIAGEN's stock price today?

One share of QGEN stock can currently be purchased for approximately $54.34.

How much money does QIAGEN make?

QIAGEN has a market capitalization of $12.39 billion and generates $1.87 billion in revenue each year. The company earns $359.19 million in net income (profit) each year or $2.15 on an earnings per share basis.

How many employees does QIAGEN have?

QIAGEN employs 5,610 workers across the globe.

What is QIAGEN's official website?

The official website for QIAGEN is www.qiagen.com.

Where are QIAGEN's headquarters?

QIAGEN is headquartered at HULSTERWEG 82, VENLO P7, 5912.

How can I contact QIAGEN?

QIAGEN's mailing address is HULSTERWEG 82, VENLO P7, 5912. The company can be reached via phone at (177) 355-6600 or via email at [email protected]

This page was last updated on 9/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.